8:35 AM
 | 
Jul 12, 2018
 |  BC Extra  |  Financial News

With $132M series A, Compass points toward the clinic

Bispecific antibody play Compass Therapeutics LLC (Cambridge, Mass.) raised $49 million Thursday in the final tranche of its series A round, bringing the round's total to $132 million.

OrbiMed Advisers...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >